News coverage about Benitec Biopharma Limited (NASDAQ:BNTC) has trended somewhat positive this week, according to Accern. Accern scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Benitec Biopharma Limited earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.413787590336 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Shares of Benitec Biopharma Limited (NASDAQ:BNTC) traded down 2.81% during mid-day trading on Wednesday, hitting $2.77. 18,580 shares of the company were exchanged. The company’s market capitalization is $28.41 million. Benitec Biopharma Limited has a 52 week low of $1.30 and a 52 week high of $5.48. The company has a 50 day moving average of $2.37 and a 200 day moving average of $2.27.

A number of analysts recently commented on BNTC shares. ValuEngine cut shares of Benitec Biopharma Limited from a “hold” rating to a “sell” rating in a research note on Thursday, August 17th. Maxim Group restated a “hold” rating on shares of Benitec Biopharma Limited in a research note on Wednesday, August 30th.

ILLEGAL ACTIVITY WARNING: This article was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/11/01/benitec-biopharma-limited-bntc-receiving-somewhat-positive-press-coverage-report-finds.html.

About Benitec Biopharma Limited

Benitec Biopharma Limited is a biotechnology company. The Company is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property (IP); development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. Its In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic.

Insider Buying and Selling by Quarter for Benitec Biopharma Limited (NASDAQ:BNTC)

Receive News & Stock Ratings for Benitec Biopharma Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma Limited and related stocks with our FREE daily email newsletter.